Alnylam Pharmaceuticals (NASDAQ:ALNY) Stock Bumped Down to “Market Perform” by Sanford C. Bernstein

Alnylam Pharmaceuticals (NASDAQ:ALNY) was downgraded by research analysts at Sanford C. Bernstein from an “outperform” rating to a “market perform” rating in a research note issued to investors on Friday, MarketBeat.com reports. They presently have a $199.00 target price on the biopharmaceutical company’s stock. Sanford C. Bernstein‘s target price would suggest a potential upside of 12.28% from the stock’s previous close.

A number of other brokerages also recently commented on ALNY. JPMorgan Chase & Co. lowered their price objective on shares of Alnylam Pharmaceuticals from $375.00 to $369.00 and set an “overweight” rating on the stock in a research report on Wednesday, September 30th. Chardan Capital reiterated a “buy” rating and issued a $425.00 target price on shares of Alnylam Pharmaceuticals in a research report on Friday, July 31st. Stifel Nicolaus lowered shares of Alnylam Pharmaceuticals from a “buy” rating to a “hold” rating and set a $225.00 target price for the company. in a research note on Thursday. Raymond James Financial cut shares of Alnylam Pharmaceuticals from a “strong-buy” rating to an “outperform” rating and lowered their price target for the company from $420.00 to $315.00 in a report on Friday. Finally, Zacks Research downgraded shares of Alnylam Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a research note on Friday, October 23rd. Two investment analysts have rated the stock with a Strong Buy rating, fifteen have issued a Buy rating and nine have assigned a Hold rating to the company. Based on data from MarketBeat, the company has an average rating of “Moderate Buy” and a consensus target price of $334.48.

Alnylam Pharmaceuticals Price Performance

Alnylam Pharmaceuticals stock traded up $3.24 during midday trading on Friday, hitting $177.24. The company’s stock had a trading volume of 371,324 shares, compared to its average volume of 1,486,453. The stock’s 50-day moving average price is $237.78 and its 200-day moving average price is $287.22. The company has a market capitalization of $23.72 billion, a PE ratio of 33.10 and a beta of 0.28. The company has a quick ratio of 2.99, a current ratio of 3.05 and a debt-to-equity ratio of 0.75. Alnylam Pharmaceuticals has a 12 month low of $170.69 and a 12 month high of $479.79.

Alnylam Pharmaceuticals (NASDAQ:ALNY) last issued its earnings results on Thursday, October 29th. The biopharmaceutical company reported $16.26 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.66 by $14.60. The business had revenue of $1.46 billion for the quarter, compared to analysts’ expectations of $1.43 billion. Alnylam Pharmaceuticals had a return on equity of 84.93% and a net margin of 15.26%. The company’s quarterly revenue was up 16.7% on a year-over-year basis. During the same period in the previous year, the firm posted $2.90 EPS. Analysts anticipate that Alnylam Pharmaceuticals will post 6.43 earnings per share for the current fiscal year.

Insider Activity at Alnylam Pharmaceuticals

In other news, EVP Bryan Supran sold 1,758 shares of Alnylam Pharmaceuticals stock in a transaction dated Friday, October 2nd. The shares were sold at an average price of $226.88, for a total transaction of $398,855.04. Following the sale, the executive vice president directly owned 12,807 shares in the company, valued at approximately $2,905,652.16. The trade was a 12.07% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Insiders own 0.86% of the company’s stock.

Institutional Trading of Alnylam Pharmaceuticals

Large investors have recently made changes to their positions in the business. Wellington Management Group LLP increased its position in shares of Alnylam Pharmaceuticals by 9.0% in the 2nd quarter. Wellington Management Group LLP now owns 2,110,407 shares of the biopharmaceutical company’s stock valued at $635,296,000 after buying an additional 174,482 shares in the last quarter. Legal & General Group Plc bought a new position in Alnylam Pharmaceuticals during the second quarter worth about $278,321,000. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC lifted its holdings in Alnylam Pharmaceuticals by 7.4% during the second quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 727,848 shares of the biopharmaceutical company’s stock worth $219,104,000 after acquiring an additional 50,329 shares in the last quarter. Bank of New York Mellon Corp acquired a new position in Alnylam Pharmaceuticals in the second quarter valued at about $148,128,000. Finally, Swiss National Bank grew its stake in Alnylam Pharmaceuticals by 7.9% in the first quarter. Swiss National Bank now owns 387,720 shares of the biopharmaceutical company’s stock valued at $128,285,000 after acquiring an additional 28,520 shares during the period. Institutional investors own 92.97% of the company’s stock.

More Alnylam Pharmaceuticals News

Here are the key news stories impacting Alnylam Pharmaceuticals this week:

• Positive Sentiment: Alnylam reported third-quarter revenue of $1.46 billion, up 16.7% year over year and ahead of the $1.43 billion consensus estimate. Reported earnings of $16.26 per share also exceeded expectations, while the company maintained its fiscal 2026 product-sales outlook. Alnylam Pharmaceuticals third-quarter earnings report
• Positive Sentiment: Management projects 2026 TTR product sales of approximately $4.2 billion to $4.5 billion, supported by continued demand for Amvuttra. The company also reaffirmed its development plans for nucresiran and expanded the TRITON-CM study to roughly 2,250 patients while maintaining an expected launch timeframe around 2030. Alnylam TTR sales and TRITON-CM update
• Positive Sentiment: The quarter’s earnings included a substantial tax benefit, reportedly contributing roughly $1.9 billion to the unusually large EPS beat. Analysts also cited encouraging brezosiran data as a potential source of longer-term value. Alnylam Q3 tax benefit and earnings analysis
• Neutral Sentiment: Trading in ALNY was temporarily halted under a volatility-related LULD pause, reflecting unusually sharp market activity following the earnings release.
• Negative Sentiment: The large EPS beat was driven heavily by the tax windfall rather than recurring operating performance. Investors may therefore place greater weight on product sales and forward guidance than on reported earnings.
• Negative Sentiment: Reports indicated that U.S. Amvuttra and Onpattro sales growth slowed, raising concerns about the pace of TTR franchise expansion despite the company’s full-year outlook. Alnylam product sales growth report
• Negative Sentiment: Stifel downgraded Alnylam from Buy to Hold with a $225 price target, while Needham cut its target from $357 to $243, signaling reduced near-term upside and heightened execution concerns. Stifel Alnylam downgrade
• Negative Sentiment: Alnylam’s decision to expand the nucresiran heart trial again increases development costs and may prolong the path to commercialization. Separately, a law firm announced an investigation related to a prior company disclosure, adding a legal-overhang risk. Alnylam nucresiran study update

About Alnylam Pharmaceuticals

Alnylam Pharmaceuticals, Inc is a biopharmaceutical company focused on developing and commercializing medicines based on RNA interference (RNAi). The company’s therapies are designed to silence specific genes involved in disease, with the goal of addressing the underlying causes of genetic and other serious conditions.

Alnylam’s marketed products include ONPATTRO (patisiran) and AMVUTTRA (vutrisiran) for hereditary transthyretin-mediated amyloidosis, GIVLAARI (givosiran) for acute hepatic porphyria, and OXLUMO (lumasiran) for primary hyperoxaluria type 1.